Our proprietary Trimer-Tag© technology platform is a product development platform for the creation of novel vaccines and biologic therapies to address the world’s most life-threatening diseases and public health threats. Our Trimer-Tag© technology platform can trimerize any protein of interest and target a broad spectrum of naturally trimerization-dependent disease and biologic targets. By employing our Trimer-Tag© technology platform, we are able to produce innovative, covalently-trimerized fusion proteins to effectively target previously difficult to target pathways.
Globally, Trimer-Tag© is the only trimerization technology platform for designing and producing recombinant, secreted, covalently-linked trimeric fusion proteins (trimer-tagged proteins) exploiting a human-derived trimerization tag.
The following diagram highlights our Trimer-Tag© technology platform and the naturally trimerization-dependent disease and biologic targets that could potentially be addressed by harnessing our technology: